Orforglipron: The First Oral Small-Molecule GLP-1 Agonist
Non-peptide GLP-1 agonist in Phase 3. Daily oral pill, no food/water restrictions. ~15% weight loss in Phase 2.
๐ฅ Human studies
- Full name
- Orforglipron (LY3502970)
- Class
- Small-molecule GLP-1 receptor agonist
- Half-life
- 29โ49 hours
- Route
- Oral daily
- Developer
- Eli Lilly
- Regulatory status
- FDA-approved 1 April 2026 as Foundayo (obesity) โ first oral GLP-1 weight-loss pill, no food/water timing restrictions. Lilly.
What it is
Orforglipron is a non-peptide small-molecule GLP-1 agonist, unique among incretin drugs. Unlike Rybelsus (oral semaglutide, a peptide requiring SNAC and strict dosing conditions), orforglipron is inherently orally bioavailable with no food or water restrictions. Developed by Eli Lilly, it is expected to launch 2025 as the first pill-form GLP-1 for obesity.
How it works
Orforglipron binds an allosteric site on the GLP-1 receptor distinct from native GLP-1's orthosteric binding pocket. This biased agonism recruits G-protein signalling efficiently while reducing ฮฒ-arrestin-mediated receptor internalisation.
Effects are classic GLP-1 physiology: insulin secretion, glucagon suppression, delayed gastric emptying, central satiety. Once-daily oral dosing eliminates needle aversion, the leading barrier to GLP-1 uptake.
What the research shows
Phase 2 data in obesity and T2D are the basis for ongoing Phase 3 programmes.
Wharton S et al. (2023) โ Phase 2 obesity trial
Wharton S. et al., NEJM 2023;389:877โ888. ๐ฅ Human studies
272 adults with obesity randomised to orforglipron 12/24/36/45 mg daily or placebo for 36 weeks.
Weight loss 8.6โ12.6% (vs 2.0% placebo). Nausea/vomiting dose-dependent but tolerable.
Limitations: Short duration; dose selection for Phase 3 was 36 mg.
Frias JP et al. (2023) โ Phase 2 T2D trial
Frias J.P. et al., Lancet 2023;402:472โ483. ๐ฅ Human studies
383 T2D patients, 26-week Phase 2.
HbA1c โ1.7 to โ2.1% vs โ0.4% placebo; weight โ5.4 kg to โ9.2 kg.
Limitations: Higher GI adverse events at top doses.
Safety and limitations
GI effects mirror injectable GLP-1s: nausea (22โ47%), constipation, diarrhoea. Dose titration typical over 12 weeks. Hepatic safety reassuring across Phase 2.
As with all GLP-1s: pancreatitis risk, rodent C-cell tumour class warning, MTC/MEN2 contraindication. Phase 3 data pending.